Lack of effect of short-term depletion of plasma complement C3 on the survival of syngeneic dopaminergic neurons following grafting into the intact rat striatum.
Metabolically compromised cells may be subject to complement-mediated cytotoxicity. The aim of this study was to clarify to what extent plasma complement C3 might contribute to the low survival (5-20%) of grafted dopaminergic neurons. The survival of intrastriatal cell suspension grafts of syngeneic dopaminergic, tyrosine hydroxylase (TH)-containing neurons was compared in rats subjected to short-term i.v. treatment with 1) cobra venom factor (CVF), or 2) placebo treatment. Depletion of plasma complement C3 by CVF was confirmed by crossed immunoelectrophoresis. With 159 +/- 37 (mean +/- SEM) TH-immunoreactive and 154 + /- 40 TH mRNA-expressing neurons in the CVF-treated rats (n = 9), and 117 +/- 34 TH-immunoreactive and 160 +/- 49 TH mRNA-expressing neurons in placebo rats (n = 6), the CVF treatment did not increase the survival of the grafted dopaminergic neurons. Similarly, CVF had no apparent effect on the astroglial, microglial, or oligodendroglial cell response within and around the graft. The data indicate that depletion of plasma complement C3 at the time of grafting has no effect on the long-term survival of syngeneic ventral mesencephalic dopaminergic neuronal grafts.
Khorooshi
M H
MH
Department of Anatomy and Neurobiology, Odense University, Denmark.
Meyer
M
M
Pedersen
E B
EB
Finsen
B
B
D000818:Animals; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000954:Antigens, Surface / Q000032:analysis; D030161:Avian Proteins; D051926:Basigin; D001798:Blood Proteins; D016380:Brain Tissue Transplantation / Q000379:methods / Q000502:physiology*; D003176:Complement C3 / Q000037:antagonists & inhibitors*; D003342:Corpus Striatum / Q000166:cytology; D004546:Elapid Venoms / Q000494:pharmacology*; D016332:Fetal Tissue Transplantation / Q000379:methods / Q000502:physiology*; D005333:Fetus; D005865:Gestational Age; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D006085:Graft Survival / Q000187:drug effects*; D016177:Macrophage-1 Antigen / Q000032:analysis; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis; D009474:Neurons / Q000166:cytology / Q000502:physiology / Q000637:transplantation*; D051381:Rats; D011921:Rats, Inbred WKY; D014158:Transcription, Genetic; D014185:Transplantation, Isogeneic; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis / Q000235:genetics
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D030161:Avian Proteins; D001798:Blood Proteins; C102624:Bsg protein, Gallus gallus; C079432:Bsg protein, rat; D003176:Complement C3; D004546:Elapid Venoms; D005904:Glial Fibrillary Acidic Protein; D016177:Macrophage-1 Antigen; D008562:Membrane Glycoproteins; C016310:cobra venom factor; D051926:Basigin; D014446:Tyrosine 3-Monooxygenase